Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Teva
Argus Health
Fuji
Cerilliant
QuintilesIMS
Citi
Mallinckrodt
Deloitte

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,198,871

« Back to Dashboard

Which drugs does patent 9,198,871 protect, and when does it expire?

Patent 9,198,871 protects CREON and is included in one NDA.

This patent has forty-two patent family members in twenty-two countries.
Summary for Patent: 9,198,871
Title:Delayed release pancreatin compositions
Abstract: An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent.
Inventor(s): Shlieout; George (Sehnde, DE), Koelln; Claus-Juergen (Neustadt, DE), Sczesny; Frithjof (Hannover, DE), Onken; Jens (Barsinghausen, DE), Koerner; Andreas (Springe, DE)
Assignee: Abbott Products GmbH (Hanover, DE)
Application Number:11/464,754
Patent Claim Types:
see list of patent claims
Compound; Process; Use; Dosage form; Composition; Formulation;

Drugs Protected by US Patent 9,198,871

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725-002 Apr 30, 2009 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY ➤ Sign Up
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725-004 Jul 12, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY ➤ Sign Up
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725-001 Apr 30, 2009 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY ➤ Sign Up
Abbvie CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725-005 Mar 14, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Deloitte
Daiichi Sankyo
Chinese Patent Office
Julphar
Fuji
Accenture
Cipla
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.